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Summary Circulating immune complexes (CICs) containing polymorphic epithelial mucin (PEM/MUC-J)
were found in sera of 24.5% of 151 primary breast carcinoma patients and 18-21.4% of patients with
advanced ovarian (n = 56) and breast carcinomas (n = 61), 37% of patients with benign breast tumours, but in
only 2.1% of 96 healthy individuals. The incorporation of PEM into CICs affects the detection of circulating
PEM in commercial immunoassays such as the CA 15-3 assay, as suggested by a negative correlation between
levels of PEM-containing immune complexes (PEM-CICs) and CA 15-3 values, and confirmed by isolation of
PEM from CA 15-3-negative sera containing high levels of PEM-CICs. The amounts of PEM masked by
human antibodies correspond to significant values of the CA 15-3 assay when monitoring patients for
carcinoma. Most antibodies in PEM-CICs were of IgG class, suggesting their specific nature to the PEM
epitopes.
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Human polymorphic epithelial mucin (PEM) is a MUC-1
gene-encoded high molecular weight glycoprotein expressed
by most glandular epithelia (for review see Hilkens et al.,
1992). The mucin-like extracellular domain of PEM consists,
for the most part, of an array (from 30 to 90 among different
alleles) of tandem repeats (Gendler et al., 1990; Lan.et al.,
1990; Ligtenberg et al., 1990; Wreschner et al., 1990), and
each 20 amino acid repeat contains at least two potential
0-linkage sites. Utilisation of at least one of these sites
during PEM biosynthesis, and subsequent elongation and
branching of the attached 0-linked glycan, results in a
heavily glycosylated molecule (Litvinov and Hilkens, 1993).
In carcinomas, as a result of destruction of the original
tissue architecture, PEM that is being shed from the car-
cinoma cells, enters the stroma and lymph and blood vessels,
appearing in the bloodstream of patients. Levels of the cir-
culating PEM are of significant value for monitoring car-
cinoma patients (Hilkens et al., 1986). Several immunoassays
are widely used for this purpose, among them CA 15-3
(Hayes et al., 1985), CA M26 and CA M29 (Linsley et al.,
1988; Yedema et al., 1991; for review see Bon et al., 1990).
Most of these are 'sandwich' assays based on the application
of two monoclonal antibodies recognising two different
epitopes in the extracellular domain of the PEM molecule.
In 10-30% of breast and ovarian carcinoma patients with
a high tumour load these assays detect low serum levels of
PEM (Bon et al., 1990), despite the fact that the protein is
well expressed on carcinoma cells, as can be confirmed by
immunohistological studies (Zotter et al., 1988). One of the
possible explanations for such a contradiction might be a
masking effect produced by human autoantibodies that bind
to the circulating PEM molecules, preventing an efficient
detection of PEM in immunoassays.
Incomplete or deficient glycosylation of the PEM
molecules has been demonstrated for carcinoma cells as com-
pared with the normal tissue cou,nterpart (Girling et al., 1989;
Hull et al., 1989; Litvinov and Hilkens, 1993), and, as a
result, antigenically changed PEM appears in circulation.
Therefore, a specific humoral response against PEM peptide
epitopes that are normally masked by glycosylation might be
expected. A single case of a B-cell autoimmune response
against PEM in a carcinoma patient was reported (Rughetti
et al., 1993). Additionally, the presence of autoantibodies
reactive with various carbohydrate groups has been described
in a substantial percentage of breast carcinoma patients (Bar-
bacid et al., 1980). Some of these carbohydrate-reactive
autoantibodies may also react with oligosaccharide epitopes
of the PEM molecule.
Here we report that approximately one in every five car-
cinoma patients was shown to have circulating PEM
molecules included into immune complexes, which are,
therefore, not efficiently detected in the CA 15-3 assay. PEM
was isolated from the PEM-CIC-positive sera that were low/
negative in the CA 15-3 assay. The amounts of PEM isolated
were comparable with those usually found in sera that show
high values of circulating PEM (140 U ml-') in the CA 15-3
assay.
Materials and methods
Patients and sera
Serum samples were obtained from (1) 151 patients with
breast cancer (mean age 59 years, range 31-88) before
primary treatment; (2) 61 breast cancer patients (mean age 56
years, range 33-79) with recurrent or progressive disease and
a high tumour load; (3) 56 ovarian carcinoma patients (mean
age 56 years, range 26-84); (4) 40 patients with benign breast
dysplasias and tumours: ten fibroadenomas, 30 with
fibroadenosis (mean age 46.5 years, range 22-83). As cont-
rols we used sera of 96 apparently healthy women (mean age
47 years, range 39-72). Serum samples were collected, ali-
quoted and stored at - 70°C until analysed.
Monoclonal antibodies
The following murine antibodies (MAbs) against PEM were
used: MAb 139H2, reacting with a repetitive peptide epitope
that is unmasked on the majority of PEM's glycoforms (Lit-
vinov and Hilkens, 1993), MAb 1 15D8 recognising a composite
protein-carbohydrate epitope on the PEM molecule and MAb
GPI.4 (raised against human milk fat globule), which is similar
to 139H2, but even less sensitive to the glycosylation of PEM in
recognition of its epitope (unpublished data).
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To detect circulating immune complexes containing PEM
molecules (PEM-CIC), a PEM-specific murine MAb 139H2
(unless other specified) and normal mouse IgGs, 5 fig per well
in phosphate-buffered saline (PBS) were adsorbed in alternate
rows in 96-well enzyme-linked immunosorbent assay
(ELISA) plates during overnight incubation at 4°C. After
three washings with PBS containing 0.05% Tween 20, the
wells were incubated for 3 h at 37°C with PBS/0.5% gelatin/
0.02% sodium azide to block non-specific adsorption binding
sites. The wells were washed three times with PBS/0.05%
Tween 20, and then 100 li per well of human sera previously
diluted 1:20 in PBS was applied. After overnight incubation
at 4°C, the content of the wells was aspirated, and the plates
were intensively washed, first with PBS/0.05% Tween 20
(four to five times), then with 1% Triton X-100 in PBS (three
to four times, leaving full plates to stand for 5-Omin each
time), and three more times with PBS/Tween 20 to remove
excess of detergent. After the last washing step, 100 gl of
goat anti-human Ig(G + M + A) immunoglobulins,
horseradish peroxidase conjugates (Pierce, Rockford, IL,
USA), previously diluted 1:5000 in PBS/0.05% Tween 20/
0.1% BSA, were added into each well and incubated for 2 h
at 4°C. When the classes of immunoglobulins incorporated
into immune complexes were to be determined, goat anti-
human immunoglobulin class-specific horseradish peroxidase
conjugates (Sigma, St. Louis, MO, USA) were used. The
content of the wells was then aspirated, the plates washed
seven times with PBS/0.05% Tween 20, rinsed with
demineralised water and 100yII per well of substrate solution
[tetramethylbenzidine (TMB) 0.06 mg ml-' in 0.1 mol sodium
phosphate buffer pH 6.0/0.03% hydrogen peroxide], was
added for 30 min. The reaction was then stopped with 1 N
sulphuric acid and quantified at 450 nm in an ELISA reader.
The experiment was performed for each serum in duplicate.
Results are presented as a mean difference between the
readings in experimental and control wells.
Circulating PEM radioimmunoassay
Levels of the circulating PEM in human sera were deter-
mined using the CA 15-3 IRMA (Centocor, Malvern, PA,
USA). CA 15-3 is a heterologous double determinant
radioimmunoassay using two monoclonal antibodies reactive
with different multiple epitopes within the repetitive domain
of the PEM molecule: catcher antibody 115D8, and 1251-
labelled tracer antibody DF-3. A cut-off level of 30 U ml-
was used.
Immunoprecipitation ofPEM
Cellulose beads coated with donkey anti-mouse IgGs (Sac-
Cel beads, IDS, Washington, UK) were preadsorbed with
either anti-PEM MAb or normal mouse IgG (in negative
control experiments) and washed five times with washing
buffer (PBS/0.05% Nonidet P-40). Immunoadsorbtion of
PEM from each serum (100fL) was performed in parallel
with the MAb 139H2- and normal mouse IgG-precoated
beads at 4°C for 18 h at the end-to-end rotator. The beads
were washed five times with washing buffer; the
immunoprecipitates were dissolved in a sample buffer
(150 mmol of Tris-HCl pH 6.8, 6 mol of urea, 2% sodium
dodecyl sulphate (SDS), 7% ,-mercaptoethanol and 10%
glycerol) and subjected to SDS-polyacrylamide gel elect-
rophoresis (PAGE). As a positive control source of PEM for
immunoprecipitation we used the lysate of mammary car-
cinoma cells ZR-75-1. Cells were lysed in PBS/1% NP-40
buffer for 30 min at 4°C, and the lysate was clarified by
30min centrifugation at 15000g.
SDS-PAGE and immunoblotting
For the detection of PEM, the immunoprecipitates were
electrophoretically separated in 5% SDS-polyacrylamide gel
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(Laemmli, 1970) and subsequently transferred to a nitrocel-
lulose membrane by electroblotting. The membranes were
blocked by incubation in PBS/3% skim milk (2 h, room
temperature). Filters were incubated for 2-18 h at 4°C in
MAb GPI.4 solution (5-10jg ml' PBS/0.05% Tween 20),
washed five to seven times in PBS/0. 05% Tween-20. The
reacted murine antibodies were detected using the anti-mouse
Protoblot system (Promega, Madison, WI, USA).
Results
Incidence of (PEM-CIC) in human sera
To detect the presence of CICs containing PEM in human
sera we used the assay employing as catcher a PEM-specific
MAb, and peroxidase-conjugated anti-human immuno-
globulin antibodies as tracer. Since human sera may contain
antibodies cross-reactive with murine IgG, we used normal
mouse IgG as a control. For each serum the reaction in the
control well (normal mouse IgG) was subtracted from the
reaction in the experiment well (MAb 139H2), and the
difference was considered to be a result of specific detection
of PEM-containing CICs. The best sensitivity for the detec-
tion of PEM-CICs was obtained with a serum dilution 1:20.
At higher dilutions only very high levels of PEM-CICs could
be detected. The control subtraction approach was chosen
because, with this dilution, background reactivity among in-
dividual sera still varied considerably. Background reactivity
of sera with control murine IgG did not differ significantly
(P = 0.5-0.8; Mann-Whitney U-test between different groups
of donors (carcinoma patients and healthy controls). Back-
ground reactivity was also not affected by variations in CA
15-3 levels.
In the assay described above with MAb 139H2 as catcher,
the PEM-CIC levels in sera ofhealthy controls were found to
exceed values above 0.1 optical density (OD) units in only 2
of 96 cases (Figure 1). On this basis an upper level of normal
PEM-CIC value of0.1 OD was chosen, thus including 97.5%
of the healthy population. With this cut-off level, 24.5% of
primary breast carcinoma patients, and 18% and 21.4% of
breast and ovarian carcinoma patients respectively, with
advanced stage of disease were positive for the presence of
PEM-CIC (Figure 1). Incidence of PEM-CIC in patients with
benign breast tumours was even higher: 37% (Figure 1).
To verify our results, we also tested the same sera in a
PEM-CIC assay employing as catchers two other monoclonal
antibodies against PEM that differ in their epitopes on the
PEM molecule: GPA.4 (isotype IgGl), and 115D8 (of IgG2a
isotype). Most of the anti-mouse IgG reactivity of human
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Figure 1 Incidence of circulating immune complexes containing
PEM in sera of healthy women, benign breast tumour patients
and carcinoma patients. The sera were analysed in the PEM-CIC
assay as described in Materials and methods. The data obtained
are presented as intensity of the reaction obtained in optical
density units. An arbitrary cut-off level of 0.1 OD was chosen.
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sera is isotype related, therefore the use of different catchers
provided additional control for the specificity of the assay.
Although absolute values varied to a certain extent (which is
to be expected because of the differences in epitopes on PEM
recognised by these catchers), in general the results obtained
in assays employing different catcher MAbs correlated well
by linear regression analysis. Significant linear correlation
between assays employing 139H2 and GPI.4 was found
(r = 0.638, P<0.008), also between the data obtained in
assays with 139H2 and 115D8 (r=0.493, P<0.01), and
GP1.4 and 1 15D8 (r<0.553, P = 0.005).
The results of the assay were reproducible when the ali-
quoted samples of sera were used since repetitive freez-
ing-thawing of the sera affected the results of the assay
greatly. The intra-assay coefficient of variation was between
5% and 11% as expected in solid-phase immunoassays, inter-
assay variations, however, were between 13% and 26%. The
absence of a standard positive control that can be titrated
and used as a reference in every test to obtain a calibration
curve constitutes a problem. For this reason, evaluated
results were obtained in a single assay.
Negative correlation between PEM-CIC and PEM levels
Levels of circulating PEM were measured in all sera using
the CA 15-3 assay and related to the level of PEM-CICs
found for each serum.
Among ovarian carcinoma patients (Figure 2a) the highest
levels ofcirculating PEM occurred in sera with relatively low
levels of PEM-CIC. Those sera with the highest levels of
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PEM-CIC contained low or intermediate levels of PEM.
Similar observations were made for breast carcinoma patients
(data not shown).
By least squares regression analysis a linear relation was
found between the levels of PEM-CICs and circulating PEM
in the group of carcinoma patients having elevated levels of
either PEM-CICs (>0.15 OD) or PEM (CA 15-
3>100Uml-'). The slope was -0.1627 (95% confidence
interval -0.2532 to -0.0722) and the y-axis intercept 0.215
OD (r = 0.4096, Sy/x = 0.144, P= 0.0006, n = 67) (Figure
2b). Non-parametric statistical analysis (Mann-Whitney U)
showed a highly significant difference (P<0.0001) between
PEM-CIC levels in sera with high (>l00Uml-') and low
(<l00Uml-') CA 15-3 values respectively.
Isolation ofPEMfrom sera negative in the CA15-3 assay
To confirm that sera with high levels of PEM-CICs do
contain PEM molecules that are not efficiently detected in the
CA 15-3 assay, we performed an immunoprecipitation of
PEM from human sera. We presumed that PEM included
into CIC can be precipitated, since at least part of such
complexes was detected in the PEM-CICs assay using a
PEM-specific catcher MAb. In other words, although the real
amount of PEM cannot be measured in the CA 15-3 assay,
since most of the epitopes on the molecule are masked by
human immunoglobulins, some epitopes on PEM are still
available for the binding of anti-PEM MAbs. The sera
selected for this study were positive in either the CA 15-3
assay (CA 15-3>30 Uml-'; PEM-CIC<0.1 OD; n = 3) or
the PEM-CIC assay (PEM-CICs >0.2 OD; CA 15-3 <30 U
ml-'; n = 5). Control sera were either positive (n = 1), or
negative in both assays (healthy controls, n = 1; ovarian
cancer patients serum, n = 1). The immunoprecipitation was
performed as described above, and immunoprecipitations
were analysed by immunoblotting with MAb GPA.4. Figure 3
shows that this approach enabled the detection of PEM
precipitated from the lysate of PEM-positive ZR-75-1 mam-
mary carcinoma cells (positive control for immunoprecipita-
tion). A typical band corresponding to the PEM molecule
was also detected in an immunoprecipitate from serum with a
high value in the CA 15-3 assay (140 U ml-', serum Mtl6),
but not from normal donor serum (CA 15-3 = 8 U ml- ',
serum Ndl) and not from ovarian cancer patients' serum,
both of which have low values (20 U ml-', 0.03 OD, serum
Ot36, Figure 3). PEM was also precipitated and detected by
immunoblotting with MAb GPA.4 from three out of five sera
with very low levels of CA 15-3 (<30 U ml-'), and high
levels of PEM-CIC (>0.2 OD). As could be visually
PEM-CICs = -0.1627 x CA 15-3 + 0.215
r = 0.4069
P =-0.0006
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Figure 2 Negative correlation between the values of circulating
PEM, as defined by the CA 15-3 assay, and PEM-CIC values. (a)
The relative values of PEM-CICs and CA 15-3 in sera from
ovarian carcinoma patients that have high levels of either cir-
culating PEM (>200 U ml-', hatched circles) or PEM-CICs
(>0.2 OD, black circles. (b) A negative correlation trend for the
values of PEM-CICs and of circulating PEM (CA 15-3) for all
sera with either high levels of PEM (> 100 U ml-') or high levels
of PEM-CICs (>0.15 OD).
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Figure 3 Immunoprecipitation of PEM from human sera (Ot,
ovarian; Mt, breast carcinoma patients; Nd, healthy donor). ZR,
immunoprecipitation with MAb 139H2 from a cell lysate of
ZR-75-1 mammary carcinoma cells (positive control).
Immunoprecipitations were performed from human sera in
parallel with anti-PEM MAb 139H2 (lanes 2,4,6 and 8) and
normal murine IgG (lanes 1,3,5 and 7). Immunoprecipitates were
separated by PAGE under reducing conditions and transferred
onto nitrocellulose filters. The Western blots were probed with
MAb GPI.4.
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-%.-estimated from immunoblots, the amount of PEM
precipitated from two of these sera (one serum: Ot41;
5 U ml-', 0.27 OD presented in Figure 3) was relatively
similar to that from an equal volume of serum with high
level of CA 15-3 (140 U ml-', 0.27 OD, serum Mtl6, Figure
3). The differences in the molecular weight of PEM
precipitated from different sera can be related to individual
allele variations (Litvinov and Hilkens, 1993), and may also
be due to individual differences in glycosylation of the PEM
molecules.
Classes ofhuman antibodies involved in the PEM-containing
immune complexes
Sera positive in the PEM-CIC assay (n = 15) were tested in
an assay similar to the PEM-CIC assay, but using anti-
human Ig/class-specific tracer antibodies. The data obtained
for a representative selection of these sera (n = 8) are present-
ed in Figure 4. Immunoglobulins of IgG class prevailed
among immunoglobulins involved in formation of the PEM-
CIC in all sera tested. The presence of a substantial fraction
of IgM class antibodies in PEM-CICs usually correlated to
high levels of IgGs as well; in only one serum we found
mainly IgM to be involved in the PEM-CICs. In two serum
samples only IgG class antibodies were detected in the PEM-
CICs. No high levels of IgA in PEM-CICs were found in the
sera analysed.
Discussion
In the present study we demonstrated the existence of
autoantibodies reactive with polymorphic epithelial mucin in
sera from breast and ovarian carcinoma patients that form
circulating immune complexes incorporating PEM molecules.
Our data suggest that such an immune response occurs in
approximately 20% of all carcinoma patients, in whom cir-
culating PEM was found to be bound to circulating immune
complexes.
The autoantibodies involved in PEM-containing immune
complex formation were mainly found to be of IgG class
(Figure 4), suggesting that, at least in part, they appeared as
a result of a specific immune response against the PEM
molecules. Kotera et al. (1994) demonstrated in 10% of sera
from carcinoma patients the presence of IgMs reactive with
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Figure 4 Classes of human antibodies involved in PEM-CICs.
Sera positive in the PEM-CIC assay were tested in a similar assay
using class-specific anti-human Ig conjugate as described in
Materials and methods. The relative values for IgA, IgG and
IgM detected are represented as a trend for each serum tested in
optical density units.
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the peptide-representing repetitive domain of the PEM
molecule. With respect to these data there is a question of
whether anti-PEM antibodies involved in PEM-CICs are
directed against protein epitopes on the PEM molecule or
against the carbohydrate or against mixed carbohydrate-
protein epitopes. The presence of antibodies to carbohydrate
epitopes similar to those present on the PEM molecule in
sera ofcarcinoma,patients was reported previously (Barbacid
et al., 1980), although it is difficult to determine whether their
appearance is indeed an immune reaction against PEM. In
this respect, it is important that recently (M Gourevitch et al.
manuscript in preparation) a substantial number of sera used
in the present study were found to be reactive with a syn-
thetic peptide representing a triple tandem repeat from the
repetitive domain of the PEM molecule. Such a peptide
antigenic determinant represents a unique sequence of the
PEM repeat in its natural conformation (Fontenot et al.,
1993), strongly suggesting a high specificity of human
antibodies reactive with it. Nevertheless, the absence on the
synthetic PEM repeat of 0-linked glycans, which are nor-
mally present on the PEM molecule, may affect the binding
of a certain fraction of autoantibodies against PEM that
recognise epitopes including carbohydrates chains; we cannot
exclude the possibility that they cannot be detected using
peptide antigenic determinant only. A further investigation of
anti-PEM response is required to characterise the epitope
specificity of autoantibodies, especially when considering an
application of synthetic antigenic determinants of PEM for
vaccination of carcinoma patients.
One plausible explanation for the appearance of anti-PEM
autoantibodies in carcinoma patients is that PEM expressed
in carcinoma cells is often aberrantly glycosylated or has low
glycosylation (Girling et al., 1989; Hull et al., 1989; Hilkens
et al., 1992; Litvinov and Hilkens, 1993), and therefore car-
ries both protein and carbohydrate epitopes which are not
exposed on PEM synthesised by normal cells. In normal
individuals immunogenic epitopes of PEM evade immuno-
logical recognition because they are masked by 0-linked
glycans of the heavily glycosylated PEM molecule produced
by normal glandular epithelia. The molecules with a changed
antigenic profile might be immunogenic, as has been shown
for some other proteins sharing common structural features
with PEM. Thus, autoantibodies were found against
leucosialin (Ardman et al., 1990), a highly 0-glycosylated
leucocyte surface protein immunologically resembling PEM
by combination of linear protein and carbohydrate epitopes.
Also, autoantibodies reactive with a tandem repeat domain
of the PEM molecule have been demonstrated in patients
with ulcerative colitis (Hinoda et al., 1993). A single case of
humoral immune response against PEM was also recently
reported by Rughetti et al. (1993), who isolated a B-cell
producing antibodies against PEM peptide epitope from an
ovarian cancer patient. Cytotoxic lymphocytes reactive with
PEM-expressing cells were found in an ovarian cancer
patient (Ioannides et al., 1993).
Another reason for the immune response against PEM, an
antigen that is also expressed by normal tissue, is its in-
creased exposure to the immune system in carcinoma
patients. In normal tissue PEM is present almost exclusively
at the apical domain of the glandular epithelia (Zotter et al.,
1988). During carcinogenesis tumour cells invade the stroma
or metastasise into other tissues, constantly supplying PEM
molecules to the immune presentation system of the patient.
It is plausible to expect that incorporation ofPEM into CICs
would lead to enhanced consumption of the circulating PEM
by macrophages or dendritic cells with the subsequent pres-
entation of the PEM molecule to the immune system of the
patient.
Little is known about glycosylation of PEM in cells of
benign breast dysplasia or about the pathways of antigen
supply into patients' circulation. Nevertheless, elevated levels
ofPEM can be detected in the circulation ofsuch patients, as
could be detected by the CA 15-3 assay (Bon et al., 1990).
Whether the high frequency of PEM-reactive antibodies
detected in this group of patients can be explained in theMUC-1 mucin-containing immune complexes in carcinoma patients
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same way as in carcinoma patients and whether the
specificity of antibodies differs in patients with malignant and
benign tumours are subjects for further investigation.
One of the important aspects of the results presented is an
observed negative effect of binding of the PEM to CICs on
its detection in commercially available immunoassays which
are in clinical use for cancer monitoring. We have detected
high levels of PEM-CICs in some sera in which only low
levels of circulating PEM were found. As has been demon-
strated here, the true levels of PEM might not be detected by
the CA 15-3 assay as a result of a masking effect by human
antibodies. This was confirmed by isolation of PEM
molecules from sera that were low/negative in the CA15-3
assay; the real amounts of circulating PEM in those sera
could correspond to the relatively high values of the CA 15-3
assay (Figure 3).
The detection of circulating PEM in sera of carcinoma
patients has proven to be important for monitoring of car-
cinoma patients (for review see Bon et al., 1990). All
immunoassays for PEM are based on the use of antibodies
against epitopes in the repetitive domain of the PEM
molecule. Usually between 3 and 10 MAbs (depending on the
number of repeats) can react with the whole PEM molecule,
and therefore all assays measure the number of free epitopes
rather than the true number of PEM molecules. Developing
the assay for PEM-CICs we presumed that at least a few
epitopes on PEM, bound to CICs, are available for the
binding of the catcher MAb, while not being sufficient for the
effective binding of the tracer. This explanation seems to be
correct, since we were able to detect PEM-CICs in human
sera using not only MAb 139H2, but also MAb 115D8,
which is used as a catcher MAb in the CA 15-3 assay.
However, we cannot exclude the possibility that, in some sera
with very high levels of PEM-reactive autoantibodies, there
are complexes present which we cannot detect in our assay,
since all free epitopes on PEM molecules are masked by the
human antibodies. Nevertheless, the PEM-CIC assay pro-
vides additional information on the levels of circulating
PEM. Our recent data (Svon Mensdorff-Pouilly et al., in
preparation) suggest that the detection of PEM-CICs in car-
cinoma patients may provide an additional source of
clinically valuable information of prognostic significance
complementary to that provided by CA 15-3.
Abbreviations
PEM, polymorphic epithelial mucin; PEM-CIC, PEM-containing cir-
culating immune complex; OD, optical density units; PAGE, polyac-
rylamide gel electrophoresis; MAb, monoclonal antibody.
Acknowledgements
The authors wish to thank the Biocare foundation for financial
support (Biocare Grant 93/04) and Dr S Susumura for technical
assistance.
References
ARDMAN B, SIKORSKY MA, SETTLES M AND STAUNTON DE.
(1990). Human immunodeficiency virus type 1-infected individ-
uals make autoantibodies that bind to CD43 on normal thymic
lymphocytes. J. Exp. Med., 172, 1151-1158.
BARBACID M, LONG L AND AARONSON SA. (1980). Major struc-
tural proteins of type B, C, and type D oncoviruses share inter-
species antigenic determinants. Proc. Nati Acad. Sci. USA., 77,
72-76.
BON GG, KENEMANS P, VAN KAMP GJ, YEDEMA CA AND HILGERS
J. (1990). Review on the clinical value of polymorphic epithelial
mucin tumour markers for the management of carcinoma
patients. J. Nucl. Med. Allied Sci., 34, 151-162.
FONTENOT JD, TJANDRA N, BU D, HO C, MONTELARO RC AND
FINN OJ. (1993). Biophysical characterization of one-, two-, and
three-tandem repeats of human mucin (muc-1) protein core.
Cancer Res., 53, 5386-5394.
GENDLER SJ, LANCASTER CA, TAYLOR-PAPADIMITRIOU J,
DUHIG T, PEAT N, BURCHELL J, PUMBERTON L, LALANI E-N
AND WILSON D. (1990). Molecular cloning of human tumour-
associated polymorphic epithelial mucin. J. Biol. Chem., 265,
15286-15293.
GIRLING A, BARTKOVA J, BURCHELL J, GENDLER S, GILLETT C
AND TAYLOR-PAPADIMITRIOU J. (1989). A core protein epitope
of the polymorphic epithelial mucin detected by the monoclonal
antibody SM-3 is selectively exposed in a range of primary
carcinomas. Int. J. Cancer, 43, 1072-1076.
HAYES DF, SEKINE H, OHNO T, ABE M, KEEFE K AND KUFE DW.
(1985). Use of murine monocloncal antibody for detection of
circulating DF3 plasma antigen levels in breast cancer patients. J.
Clin. Invest., 75, 1397-1402.
HILKENS J. KROEZEN V, BONFRER JMG, DE JONG-BAKKER M,
AND BRUNNING PF. (1986). MAM-6 antigen, a new serum
marker for breast cancer monitoring. Cancer Res., 46,
2582-2587.
HILKENS J, LIGTENBERG MJL, VOS HL AND LITVINOV SV. (1992).
Cell membrane-associated mucins and their adhesion-modulating
property. Trends Biol. Sci., 17, 359-363.
HINODA Y, NAKAGAWA N, NAKAMURA H, MAKIGUCHI Y, ITOH
F, ADACHI M, YABANA T, IMAI K AND YACHI A. (1993). Detec-
tion of a circulating antibody against a peptide epitope on a
mucin core protein, MUC1, in ulcerative colitis. Immunol. Lett.,
35, 163-168.
HULL SR, BRIGHT A, CARRAWAY KL, ABE M, HAYES DF AND
KUFE DW. (1989). Oligosaccharide differences in the DF3
sialomucin antigen from normal human milk and the BT-20
human breast carcinoma cell line. Cancer Commun., 1, 261-267.
IOANNIDES CG, FISK B, JEROME KR, IRIMURA T, WHARTON JT
AND FINN 0. (1993). Cytotoxic T cells from ovarian malignant
tumours can recognize polymorphic epithelial mucin core pep-
tides. J. Immunol.,151, 3693-3703.
KOTERA Y, FONTENOT JD, PECHER G, METZGAR RS AND FINN
OJ. (1994). Humoral immune response against a tandem repeat
epitope of human mucin MUC-1 in sera from breast, pancreatic,
and colon cancer patients. Cancer Res., 54, 2856-2860.
LAEMMLI UK. (1970). Cleavage of structural proteins during the
assembly of head of bacteriophage T4. Nature, 227, 680-685.
LAN MS, BATRA SK, QI WN, METZGER RS AND HOLLINGSWORTH
MA. (1990). Cloning and sequencing of a human pancreatic
tumour mucin cDNA. J. Biol. Chem., 265, 15294-15299.
LIGTENBERG MJL, VOS HL, GENNISSEN AMC AND HILKENS J.
(1990). A carcinoma-associated mucin is generated by a polymor-
phic gene encoding splice variants with alternative amino-termini.
J. Biol. Chem., 265, 5573-5578.
LINSLEY PS, BROWN JP, MAGNANI JL AND HORN D. (1988).
Monoclonal antibodies reactive with mucin glycoproteins found
in sera from breast cancer patients. Cancer Res., 48, 2138-2148.
LITVINOV S AND HILKENS J. (1993). The epithelial sialomucin,
episialin, is sialylated during recycling. J. Biol. Chem., 268,
21364-21371.
RUGHETTI A, TURCHI V, GHETTI CA, SCAMBIA G, PANICI PB,
RONCUCCI G, MANCUSO S, FRATI L AND NUTI M. (1993).
Human B-cell immune response to the polymorphic epithelial
mucin. Cancer Res., 53, 2457-2459.
WRESCHNER D, HAREUVENI M, TSARFATI I, SMORODINSKY N,
HOREV J, ZARETSKY J, KOTKES P, WEISS M, LATHE R, DION A
AND KEYDAR I. (1990). Human epithelial tumour antigen cDNA
sequences. Eur. J. Biochem., 189, 463-473.
YEMEDA CA, KENEMANS P, WOBBES T, VAN KAMP GJ, DE BRUIJIN
HW, THOMAS CM, MASSUGER LF, SCHIJF CP, BON GG, VER-
MORKEN JB, VOORHORST F, HILGERS J. (1991). Carcinoma-
associated mucin serum markers CA M26 and CA M29: efficacy
in detecting and monitoring patients with cancer of the breast,
colon, ovary, endometrium and cervix. Int. J. Cancer, 47,
170- 179.
ZOTTER S, HAGEMAN PC, LOSSNITZER A, MOOI WJ AND HILGERS
J. (1988). Tissue and tumour distribution of human polymorphic
epithelial mucin. Cancer Rev., 11-12, 55-101.